Kappa agonist compounds and pharmaceutical formulations thereof

A compound of the formula III or a pharmaceutically acceptable salt thereof ##STR156## wherein n=1-3;

• R.sub.1 and R.sub.2 are independently .dbd.CH.sub.3 ;
• --(CH.sub.2).sub.m, where m=4-8, --CH.sub.2 CH(OH)(CH.sub.2).sub.2 --;
• --CH.sub.2 CH(F)(CH.sub.2).sub.2 --;
• --(CH.sub.2).sub.2 O(CH.sub.2).sub.2 --;
• or --(CH.sub.2).sub.2 CH.dbd.CHCH.sub.2 --;
• Ar=unsubstituted or mono-, or di-substituted phenyl wherein said substituents are selected from the group consisting of halogen, OCH.sub.3, SO.sub.2 CH.sub.3, CF.sub.3, amino, alkyl, and 3,4-dichloro;
• benzothiophenyl;
• benzofuranyl;
• naphthyl;
• diphenyl methyl;
• or 9-fluorene;
• or Ar=heteroaromatic groups having 1-3 heteroatoms selected from the group consisting N, O and S and bearing 1-4 substituents selected from the group consisting of chlorobenzoyl, Br, Cl, F, alkyl, alkoxy, carboxy, carboxamided, amine, amide and sulfonamide;
• X.sub.7 is
• --NHSO.sub.2 CH.sub.3 ;
• --NHP(O)(OBn).sub.2 ;
• --NHP(O)(OH).sub.2 ;
• --(CH.sub.2).sub.u NHSO.sub.2 CH.sub.3 ;
• --(CH.sub.2).sub.u NHC(S)NHCH(CO.sub.2 H)(CH.sub.2).sub.u CO.sub.2 H;
• --CONHOH;
• or --(CH.sub.2).sub.u CONHOH;
• wherein
• u=1-5;
• or X.sub.7 is ##STR157## R.sub.6 =--H or -Ac;
• X.sub.8 =--CO.sub.2 H;
• --NHSO.sub.2 CH.sub.3 ;
• --NHP(O)(OBn).sub.2 ;
• --NHP(O)(OH).sub.2 ;
• --OP(O)(OBn).sub.2 ;
• or
• --OP(O)(OH).sub.2 ;
• R.sub.7 =--NH(CH.sub.2).sub.v CO.sub.2 H;
• --NH(CH.sub.2).sub.v CH(NH.sub.2)(CO.sub.2 H);
• --NHCH(CO.sub.2 H)(CH.sub.2).sub.v NH.sub.2 ;
• --NH(CH.sub.2).sub.v SO.sub.3 H;
• --NH(CH.sub.2).sub.v PO.sub.3 H.sub.2 ;
• --NH(CH.sub.2).sub.v NHC(NH)NH.sub.2 ;
• or
• --NHCH(CO.sub.2 H)(CH.sub.2).sub.v CO.sub.2 H;
• and
• v=1-20.